Mooren ulceration is an uncommon corneal autoimmune disease that can lead to blindness. We describe a patient with aggressive disease in whom inflammatory control was only achieved after infusion of a tumor necrosis factor α antagonist, infliximab.
A 37-year-old Nigerian man with a 14-year history of bilateral Mooren ulceration had a right corneal perforation and a desmetocele in his severely damaged left eye (Figure, A and B). Snellen visual acuity was 6/60 OD, improving to 6/36 OD with pinhole, and hand movements OS. Systemic cyclosporine at a dosage of 5 mg/kg/d and prednisolone tapering from 1 mg/kg/d and ceasing after 8 weeks were given, with 2% cyclosporine eyedrops and ofloxacin eyedrops both 3 times daily to the right eye. The right corneal perforation healed with glue and a therapeutic contact lens. However, the desmetocele in the left eye perforated during an inflammatory episode 2 months later, so mycophenolate mofetil (CellCept; Hoffman-La Roche Inc, Nutley, New Jersey) at a dosage of 1 g twice daily was added, a 12-mm corneoscleral lamellar tectonic graft and cataract extraction were carried out, and Baerveldt tube surgery was performed for intractably elevated intraocular pressure.
Bilateral Mooren ulceration. A, Right eye at the initial visit with active ulceration. B, Left eye at the initial visit with a desmetocele and advanced disease. C, Right eye with new infiltrates at the 1-o’clock position and iris prolapse at the site of perforation, under a bandage contact lens. D, Left eye following corneoscleral graft with active guttering superotemporally and a central persistent epithelial defect. E, Right eye with quiescent disease 5 months after commencing infliximab therapy and conjunctival resection. F, Left eye with quiescent disease 5 months after commencing infliximab therapy.
After 4 months of quiescence, the disease again reactivated with new infiltrates and melts resulting in a flat chamber in the right eye and new guttering in the periphery of the left corneoscleral graft (Figure, C and D). Cyclophosphamide treatment at a dosage of 100 mg/d was commenced with another course of oral prednisolone, and mycophenolate treatment was stopped. Three weeks later, the patient developed microscopic hematuria and bloody stools, so cyclophosphamide treatment had to be discontinued. Stool cultures were negative for parasites. The infiltrates and melts in the right eye continued to be active, so infliximab at a dosage of 5 mg/kg was added, combined with oral cyclosporine. The inflammation in both eyes responded rapidly to this treatment, with gradual return of the inflammation in the 2-week interval between infusions. The patient received 3 infusions over 6 weeks. A right conjunctival recession and cautery procedure was carried out after another perforation, which sealed spontaneously under a bandage lens, and mycophenolate was again added to the immunosuppressive regimen.
Following this, both corneas healed and the eyes became white, so the infliximab infusions were reduced to 6 weekly. At the last visit, 5 months after commencing infliximab treatment, the disease appears to be quiet (Figure, E and F). Snellen visual acuity is currently 6/60 OD, improving to 6/18 OD with a scleral contact lens. Unfortunately, the patient has no vision in the left eye due to the uncontrolled glaucoma. Infliximab infusions are currently being continued at decreasing intervals.
This case demonstrates how difficult Mooren ulceration can be to treat, given both the delay in onset of action and adverse effects of conventional immunosuppressive therapy. The pathogenesis of Mooren ulceration is uncertain but may involve an immune response to a corneal stromal protein (corneal antigen), which is identical to calgranulin C released by neutrophils during the host defense response to helminths.1 Infiltration of lymphocytes, macrophages, and Langerhans cells has been observed in the conjunctiva adjacent to Mooren ulceration.2
Tumor necrosis factor α is an important cytokine in the establishment and maintenance of inflammation in many autoimmune diseases, and the success of tumor necrosis factor α antagonists in immune-mediated rheumatic diseases has led to its off-label use in ocular inflammatory disease.3 Apart from inhibition of tumor necrosis factor α, infliximab also appears to induce regulatory T cells in rheumatoid arthritis4 and to induce T-cell apoptosis in Crohn disease,5 both of which might be relevant in ocular inflammation.
To our knowledge, effective treatment with tumor necrosis factor α antagonists has not previously been described in Mooren ulceration. This article shows that addition of infliximab may be useful when rapid control of inflammation is desirable and/or when conventional immunosuppressive therapy is not tolerated or effective.
Correspondence: Dr Saw, Moorfields Eye Hospital, 162 City Rd, London EC1V 2PD, England (v.saw@ucl.ac.uk).
Financial Disclosure: None reported.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
The Rational Clinical Examination Make the Diagnosis: Diabetes, Foot Ulcer
The Rational Clinical Examination Original Article: Does This Patient With Diabetes Have Osteomyelitis of the Lower Extremity?
All results at JAMAevidence.com >
and access these and other features:
Register Now
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Need assistance?
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.